Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer

/in

Dr. Gericke brings extensive experience in the research and development of radioligand therapies Appointment coincides with launch of Ariceum International AG in Basel, Switzerland Berlin, Germany, 1 February 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce […]

Read more

ViCentra bolsters leadership team with the appointment of Leo Toole as Chief Financial Officer and expands European commercialization

/in

Newly appointed CFO with significant experience in medical technology and public / private financing Insulin Pump system Kaleido to expand commercial roll out in Europe February 1, Utrecht, The Netherlands ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with type 1 Diabetes, is pleased to […]

Read more

Neuraxpharm announces closing of acquisition of established products from Sanofi

/in

Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the closing of the previously announced acquisition of two established product portfolios for CNS disorders, pain and vascular diseases from Sanofi. Read more…

Read more

Pre-launch of MED3000 Eroxon™ ahead of H1 2023 launch

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces that its partner, Cooper Consumer Health (“Cooper”) has initiated pre-launch activities ahead of the launch of MED3000 (Eroxon™), Futura’s breakthrough, topical gel formulation for the treatment of erectile […]

Read more

Destiny Pharma plc – US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections

/in

Brighton, United Kingdom – 25 January 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, notes an increased focus on the importance of infection prevention by the Center for Disease Control (“CDC”), Food and Drug Administration (“FDA”), and the medical community in […]

Read more